Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
CONCLUSIONS: There is high-certainty evidence that 5-ASA is superior to placebo, and moderate-certainty evidence that 5-ASA is not more effective than SASP. Considering relative costs, a clinical advantage to using oral 5-ASA in place of SASP appears unlikely. High-certainty evidence suggests 5-ASA dosed once daily appears to be as efficacious as conventionally-dosed 5-ASA. There may be little or no difference in efficacy or safety among the various 5-ASA formulations.
PMID: 32786164 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK Tags: Cochrane Database Syst Rev Source Type: research
More News: Asacol | Conferences | Databases & Libraries | General Medicine | Headache | Inflammatory Bowel Disease | Lialda | Migraine | Pain | Study | Ulcerative Colitis